Advanced search    

Search: authors:"Makoto Hosono"

8 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

-14-1 Kyobashi, Chuo-Ku, Tokyo 104-0031 , Japan 1 Japan Radioisotope Association , 2-28-45 Honkomagome, Bunkyo-ku, Tokyo 113-0021 , Japan 2 Makoto Hosono Here we present the guideline for the treatment

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

standards Conflict of interest Seigo Kinuya received lecture fees from Bayer, Japan. Yoko Yajima is an employee of Bayer Yakuhin, Ltd. Hiroji Uemura, Hirotsugu Uemura, Nobuaki Matsubara, Makoto Hosono and

A new shielding calculation method for X-ray computed tomography regarding scattered radiation

The goal of this study is to develop a more appropriate shielding calculation method for computed tomography (CT) in comparison with the Japanese conventional (JC) method and the National Council on Radiation Protection and Measurements (NCRP)-dose length product (DLP) method. Scattered dose distributions were measured in a CT room with 18 scanners (16 scanners in the case of the...

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Background Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. Methods In this open-label, multicenter, phase II study, patients with...

Report of a nationwide survey on actual administered radioactivities of radiopharmaceuticals for diagnostic reference levels in Japan

Objective The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and The International Committee of Radiological Protection and the International Atomic Energy Agency recommend establishing diagnostic reference levels (DRLs) as tools for dose optimization. Therefore, the development of DRLs based on the latest survey has been...

Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma

-Hodgkin's lymphoma Kohei Hanaoka Makoto Hosono 0 Yoichi Tatsumi Kazunari Ishii Sung-Woon Im Norio Tsuchiya 0 Kenta Sakaguchi 0 Itaru Matsumura 0 Division of Positron Emission Tomography, Institute of

A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy

Izumi TACHIBANA Yasumasa NISHIMURA Toru SHIBATA Shuichi KANAMORI Kiyoshi NAKAMATSU Ryuta KOIKE Tatsuyuki NISHIKAWA Kazuki ISHIKAWA Masaya TAMURA Makoto HOSONO To visualize intratumoral hypoxic areas

Clinical practice guideline for dedicated breast PET

: Dedicated Breast PET Clinical Practice Guideline Members PET Nuclear Medicine Committee Chairperson: Makoto Hosono Vice-chairperson: Tsuneo Saga Administrators: Kengo Ito, Shinichiro Kumita, Masayuki Sasaki